Canaccord Genuity analyst Edward Nash maintained a Buy rating on Apogee Therapeutics yesterday and set a price target of $89.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Edward Nash has given his Buy rating due to a combination of factors, including Apogee Therapeutics’ strong financial position and promising pipeline developments. The company has a substantial cash reserve, bolstered by a recent equity offering, which positions it well for future growth and development.
Furthermore, Apogee is entering a critical phase with several key data readouts expected in 2026. These include the Phase Ib proof-of-concept readout for asthma and multiple phases of data for atopic dermatitis, which could significantly impact the company’s market position. The potential dosing advantage of APG777 over existing treatments like Dupixent further supports the positive outlook for Apogee’s therapeutic offerings.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $95.00 price target.
APGE’s price has also changed dramatically for the past six months – from $39.580 to $63.100, which is a 59.42% increase.